At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...

Is that the case? Let's look into it and decide whether the company is worth investing in.

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and PresidentSalt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies have signed deals with it to develop drugs using its AI-based strategy. The ...

Abstract: A method of data analysis based on data representation in the form of return recursion and recursive structures generated by it is considered. Problems to be solved: description of the ...

As we conversed in his office last month, Virginia Tech athletic director Whit Babcock envisioned future revenue streams for Hokies football such as corporate logos on uniforms and the field, ads ...

Investors probably won’t sweat this week’s inflation data as they fully pencil in a Federal Reserve rate cut following clear signs the labor market is slowing down. They shouldn’t take it too far. Fed ...

I maintain a 'hold' rating on Recursion Pharmaceuticals due to mixed early-stage clinical data for FAP and uncertain pipeline progression. REC-617 showed an encouraging partial response in ...